DAFTAR PUSTAKA
Ades T et al, 2011, Cancer Recurrence,American cancer society
[AJCC ] The American Joint Committee on Cancer,2010,Seventh Edition Cancer Staging Manual and Handbook
Aman U, Buzdar., S. Eva Singletary.,Vicente, Valero., Daniel, J. Booser., Nuhad, K., Ibrahim., et al, 2002, Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial Richard L. Theriault, Ronald Walters, Clinical Cancer Research. 8:1073-1079. ).[terhubung berkala], http://clincancerres.aacrjournals.org/content/8/5/1073.full.pdf+html, [8 Juli 2013]
[ACS] American Cancer Society, 2011, Breast Cancer, Atlanta, American Cancer Society Cancer Society; 2011
Anonim, 2011, Definition of Survival Rate, National Cancer Institute Dictionary of Cancer Terms.
Anonim, 2012, Efek Samping, Jakarta, Yayasan Spiritia
Aryandono, T., et al, 1997, Protokol Onkolgi RSUP Dr. Sardjito, Yogyakarta, Gadjah Mada University Press
Bustan,M.N.2007,Epidemiologi Penyakit Tidak Menular, Jakarta, Rineka Cipta, Bontenbal ., M, Andersson., M, Wildiers., J, Cocconi., G, Jassem., J, Paridaens.,et
al., 1998, Doxorubicin vs epirubicin, report of a second.line randomized
phase 11/111 study in advanced breast cancer, British Joumal of Cancer (12):2257-2263
Bruton, L., Lazo, J. S., Parker, K. L., 2005, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, McGrawHill,
Lange.
Childs, AC., Phaneuf, SL., Dirks, AJ., Phillips, T., Leeuwenburgh. 2002. Doxorubicin treatment in vivo causes cytochromec release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and bcl-2:bax ratio.Cancer Research 62:4592-4598
Corwin EJ, 2000, Buku Saku Patofisiologi. Pendit BU, penerjemah; Pakaryaningsing, editor. Jakarta: Penerbit Buku Kedoktoran EGC. Terjemahan dari: Handbook of Pathophysiology.
[Depkes RI] Departemen Kesehatan Republik Indonesia, 2007, Petunjuk Teknis Pencegahan – Deteksi Dini Kanker Leher Rahim & Kanker Payudara.
Jakarta,Direktorat Pengendalian Penyakit Tidak Menular, Direktorat Jendral PP & PL, Departemen Kesehatan RI.
[EBCTCG] Early Breast Cancer Trialists’ Collaborative Group, 2005,Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,Lancet, 365: 1687–1717
Ellis, IO., Schinitt, SJ., Sastre, GX., et al. 2003. Invasive Breast Carcinoma in World Health Organization Classification of Tumours Pathology & Genetics Tumours of the Breast and Female Genital Organs. IARC:13-59 Fountzilas, D., Skarlos, A., Athanassiades,A., Kalogera-Fountzila, E.,
Samantas,C., Bacoyiannis, A., et al,1997, Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck, Annals of Oncology,8:451-455.
Gabriel, N. Hortobagyi., Ames, F.C., Buzdar, A.U., Kau, S.W., Paulus, D., Hug V, et al, 1988, Management of Stage III Primary Breast Cancer With Primary Chemoterapy, Surgery, and Radiation Therapy. Cancer.62: 2507-2516
Gewirtz, D.A., 1999, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem. Pharmacol., 57:727-741.
Groot, G., Rees, H., Pahwa, P., et al, 2011, Predicting local recurrence following breast-conserving therapy for early stage breast cancer: the significance of a narrow (</= 2 mm) surgical resection margin. Journal Surgery of Oncology.103:212-6.
Han, X., Pan, J., Ren, D., Cheng, Y., Fan, P., and Lou, H., 2008, Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymes, Food and Chemical Toxicology, 46:3140-3146.
Heidemann, E., Stoeger, H., Souchon, R., Hirschmann, WD., Bodenstein, H., Oberhoff, C., et al.,2002, Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial., Annals of Oncoogyl. 13:1717-1729.
Hirshaut, Yashar., Pressman, Peter I.,1992, Breast cancer : the complete guide, New York,Bantam Books
Ismaili, Nabil., Mellas, Nawfel., Masbah.,Ouafae, Elmajjaoui, Sanaa., Arifi, Samia.,et al.,2009,Concurrent chemoradiotherapy in adjuvant treatment of breast cancer, Radiation Oncology BioMedCentral 04 (12).[terhubung berkala], http://www.ro-journal.com/content/pdf/1748-717X-4-12.pdf, [3 Juli 2013]
Jolly, T., Williams, G.R., Jones E., Muss, H.B., 2012, Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older, Women’s Health.8 (04):455-471
Martha, Januar Wibawa., Surianata, Sunarya., Santoso, Amiliana., 2007,Gambaran Fungsi Diastolik Ventrikel Kiri Pada Penderita Keganasan Yang Mendapat Kemoterapi Doxorubicin, Jurnal Kardiologi Indonesia (5).[terhubungberkala],http://indonesia.digitaljournals.org/index.php/karin, [6 Oktober 2012]
Manuaba, IBTW.,2010, Panduan Penatalaksanaan Kanker Payudara Peraboi 2010. Panduan Penatalaksanaan Kanker Solid: Sagung Seto. p. 17-50.
Martin, M., Villar, A., Sole-Calvo, A., Gonzalez, R., Massuti, B., Lizon, J.,et al., 2003, Doxorubicin in Combination with fluorouracil and cyclophosphamide (i.v FAC regimen, day 1, 21) versus methrotrexate in combination with fluorouracil and cyclophosphamide (i.v CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group, Annals of Oncology (14):833-842
Minotti, G., Menna, P., Salvatorelli, E., Cairo,G., and Gianni, L. 2004. Anthracyclins: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol Rev., 56:185-228. Mintzer, D., Glassburn, J., Mason B, A., Sataloff, D., 2002, Breast cancer in the
very young patient: a multidisciplinary case presentation, The
Oncologist.7:547-554. [terhubung berkala],
http://www.ncbi.nlm.nih.gov/pubmed/12490742 , [9 Juli 2013]
Mobus,V. J., Untch, M., du Bois, A., Lueck, H.-J. , Thomssen, C., Kuhn, W., C. et al., 2004, Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial, Journal of Clinical Oncology.22: 513 Mobus, V., Schneeweiss, A., du Bois, A., Lueck, H-J., Eustermann, H., Kuhn, W.,
et al., 2012., Ten year follow-up analysis of intense dose-dense adjuvant
Naeem,M., Khan,N., Aman, Z., Nasir, A., Samad, A., Khattak, A., 2008, Pattern of breast cancer: experience at Lady Reading Hospital, Peshawar, J Ayub Med Coll Abbottabad.20:22-25
[NCCN] National Comprehensive Cancer Network, 2006, NCCN Breast Cancer Treatment Guidelines Version VIII
[NCCN] National Comprehensive Cancer Network, 2007, Breast Cancer Treatment Guidelines for Patients Version IX
Notoatmodjo., Soekidjo, 2010, Metodologi Penelitian Kesehatan, Jakarta, Rineka Cipta
Ogawa, Y., Nishioka, A., Inomata, T., Hamada,N., Terashima, M., Yoshida,S., et al., 1994, Early experiences of breast-conservation treatment combined
with tamoxifen and CAF chemotherapy for breast cancer of stages I and II, NCBI.12:29-35
Passardi, Alessandro., Massa, Ilaria., Zoli, Wainer., Gianni, Lorenzo., Milandri, Carlo., Zumaglini, Federica., et al., 2006, Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience, BioMed Central.6:76. [terhubungberkala], http://www.biomedcentral.com/1471-2407/6/76/ , [23 Juli 2013]
Payne, SJL., Bowen, RL., Jones, JL., Wells, CA., 2008. Predictivemarkers in breast cancer- thepresent. Histopathology; 52:82-90
Perwitasari, Dyah Aryani.,2006, Kajian penggunaan anti emetika pada pasien kanker dengan terapi sitostatika di rumah sakit di Yogyakarta, Majalah Farmasi Indonesia,2:91
Serrano, J., Palmeira, C. M., Kuehl, D. W., Wallace, K. B.,1999, Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim. Biophys. Acta,1411, 201–205.
Siburian, Christine Handayan ., Wahyuni, Sri Eka, 2012, Dukungan Keluarga Dan Harga Diri Pasien Kanker Payudara Di RSUP H. Adam Malik
Singletary, S.E, Allred, C., Ashley, P., Bassett, L, W., Berry, D., Bland, K,I., et al., 2002, Revision of the American Joint Committee on Cancer Staging System For Breast Cancer, Journal of Clinical Oncology.20:3628-3636 Sirait A, Oemiati R, Indrawati L. 2009. Hubungan kontrasepsi pil dengan
tumor/kanker payudara di Indonesia. Majalah Kedokteran Indonesia 59 (08).
Siregar, C.J.P., 2003, Farmasi Rumah Sakit: Teori dan Penerapan, Jakarta, buku kedokteran EGC
Smith L., Watson MB., O’Kane SL., Drew PJ., Lind MJ., Cawkwell L.,2006,The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays,Mol. Cancer Ther. 5: 2115 – 20.
Solin, LJ.,2010, Breast conservation treatment with radiation: an ongoing success story,Journal of clinical oncology,28:709
Sopiyudin,Dahlan,M.,2005,Besar Sampel untuk Penelitian Kedokteran dan Kesehatan,Arkans,Jakarta
Stephen Chan, Kay Friedrichs., Daniel Noel., Tama`s Pinte´r., Simon Van Belle., Daniel Vorobiof., et al,1999,Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer,Journal of Clinical Oncology 17:2341-2354
Tallman,Martin, S., Gray, Robert., Robert, Nicholas J., LeMaistre, Charles F., Osborne, C. Kent M.D., William P. Vaughan, M.D., et al., 2003, Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer, The New England Journal Medicine.349:17-26). [terhubungberkala],http://www.nejm.org/doi/full/10.1056/NEJMoa030684 #t=articleResults, [9 Juli 2013]
Tannock IF dan Hill RP. 1998, The Basic Science of Oncology, Ed ke-3. Singapore: McGraw-Hill.
Tilanus, LMM., Alves, C., Seynaeve, C., Menke-PMB, Eggermont, AM., Brekelmans, CT., 2007, Contralateral Recurrence and Prognosis Factors in Familial Non-BRCA ½-associated Breast Cancer. Br J Surg (8):961-968 Tjindarbumi, 1995. Diagnosis dan Pencegahan Kanker Payudara, Kursus Singkat
Deteksi Dini dan Pencegahan Kanker. 6-8 November. FKC.II-POI. Jakarta.
Vaidya, M.P., Shukla, H.S., 1983, A Textbook of Breast Cancer, New Delhi, Vikas Publishing House PVT LTD
Van de Velve. CHJ, Bosman FT, Wagener DJTh, 1999, Onkologi. Arjono,penerjemah; Yogyakarta:Panitia Kanker RSUP DR. Sardjito. Terjemahan dari: Onkologie.
Wahyuni, A.S., 2006, Hubungan Jenis Histologi dengan Ketahanan Hidup 5 Tahun. Penderita Kanker Payudara, Majalah Kedokteran Nusantara.39:1-5
Wallace, Kendall B.,2003, Doxorubicin-Induced Cardiac Mitochondrionopathy, Basic and Clinical Pharmacology & Toxicology,93,105-115
[WHO] World Health Organization,2004,The Global Burden Of Disease:Update 2004, WHO Library Cataloguing-in-Publication Data
Winarto, W.P., Vivi, K.T., Erna, C.F., Heri, Jumantoro., Nurrohman, Syahril., 2007, Pengobatan Herbal Untuk Kanker Payudara, Jakarta, Karyasari Herba Medika
Wulandari, Regina., 2012, Peran Radioterapi Eksterna Adjuvan Terhadap Penderita Kanker Payudara Stadium Lokal-Lanjut Studi Angka Harapan
Hidup Dua Tahun[karya tulis ilmiah], Semarang, Fakultas Kedokteran,
Universitas Diponegoro
